Journal
ALZHEIMERS & DEMENTIA
Volume 17, Issue 7, Pages 1145-1156Publisher
WILEY
DOI: 10.1002/alz.12283
Keywords
Alzheimer's disease; magnetic resonance imaging; phosphorylated tau; plasma biomarkers
Categories
Ask authors/readers for more resources
P-tau181 shows potential as an effective diagnostic and prognostic biomarker in AD, detecting the disease at MCI and dementia stages and being strongly associated with cognitive decline and gray matter loss.
Introduction This study investigated the diagnostic and disease-monitoring potential of plasma biomarkers in mild cognitive impairment (MCI) and Alzheimer's disease (AD) dementia and cognitively unimpaired (CU) individuals. Methods Plasma was analyzed using Simoa assays from 99 CU, 107 MCI, and 103 AD dementia participants. Results Phosphorylated-tau181 (P-tau181), neurofilament light, amyloid-beta (A beta 42/40), Total-tau and Glial fibrillary acidic protein were altered in AD dementia but P-tau181 significantly outperformed all biomarkers in differentiating AD dementia from CU (area under the curve [AUC] = 0.91). P-tau181 was increased in MCI converters compared to non-converters. Higher P-tau181 was associated with steeper cognitive decline and gray matter loss in temporal regions. Longitudinal change of P-tau181 was strongly associated with gray matter loss in the full sample and with A beta measures in CU individuals. Discussion P-tau181 detected AD at MCI and dementia stages and was strongly associated with cognitive decline and gray matter loss. These findings highlight the potential value of plasma P-tau181 as a non-invasive and cost-effective diagnostic and prognostic biomarker in AD.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available